A single chirality single walled carbon nanotubes (SWNT), and combinations thereof, can be used to detect trace levels of chemical compounds in vivo with high selectivity.

Methods, systems, compositions and kits are provided for the analysis of target molecules using chromophoric polymer dots conjugated to biomolecules. The use of chromophoric polymer dots improves detection sensitivity and stability when compared with existing techniques. In some aspects, methods, systems, and kits are provided for detecting a target protein using chromophoric polymer dots conjugated to biomolecules in a Western blot analysis. Related methods, systems, compositions and kits are also provided.

In a general aspect, an apparatus can include a substrate and a post disposed on the substrate. The post can include a plurality of nanotubes and extend substantially vertically from the substrate. The post can have an aspect ratio of a height of the post to a diameter of the post of greater than or equal to 25:1.

A method for forming nanoparticles includes forming a stack of alternating layers including a first material disposed between a second material. The stack of alternating layers is patterned to form pillars. A dielectric layer is conformally deposited over the pillars. The pillars are annealed in an oxygen environment to modify a shape of the first material of the alternating layers. The dielectric layer and the second material are etched selectively to the first material to form nanoparticles from the first material.

The invention relates to carbon nanotube-containing composites as biosensors to detect the presence of target clinical markers, methods of their preparation and uses in the medical field. The invention is particularly suitable for the detection in patient biological specimens of bone markers and tissue markers. The biosensors of the invention include carbon nanotubes deposited on a substrate, gold nanoparticles deposited on the carbon nanotubes and, binder material and biomolecule deposited on the gold-coated carbon nanotubes. The biomolecule is selected to interact with the target clinical markers. The biosensor can be used as an in-situ or an ex-situ device to detect and measure the presence of the target clinical markers.

The invention relates to carbon nanotube-containing composites as biosensors to detect the presence of target clinical markers, methods of their preparation and uses in the medical field. The invention is particularly suitable for the detection in patient biological specimens of bone markers and tissue markers. The biosensors of the invention include carbon nanotubes deposited on a substrate, gold nanoparticles deposited on the carbon nanotubes and, binder material and biomolecule deposited on the gold-coated carbon nanotubes. The biomolecule is selected to interact with the target clinical markers. The biosensor can be used as an in-situ or an ex-situ device to detect and measure the presence of the target clinical markers.

Imaging based detection of changes in extracellular neurotransmitter concentration in living tissue is achieved using novel nanotube-based sensors. The sensors are functionalized, neurocompatible single-walled carbon nanotubes (SWNT) comprising an adsorbed neurotransmitter analyte selective polynucleotide.

Fluorescent nanosensors for extracellular ion concentration measurements are disclosed herein. More specifically, a fluorescent nanosensor for extracellular ion measurements comprising a photoluminescent nanostructure disposed on a substrate surface is disclosed. The photoluminescent nanostructure comprises a fluorescent metallic core-silica shell containing nanoparticle, wherein the fluorescent silica shell comprises a fluorophore dispersed therein. The nanosensor emits a fluorescence emission in function of the extracellular ion concentration.

A process for ultrasensitive in vitro detection and/or quantification of a substance of interest in a sample is performed by detecting the luminescence emission by photoluminescent inorganic nanoparticles. The process includes (i) use of photoluminescent particles comprising a photoluminescent inorganic nanoparticle consisting of a crystalline matrix having at least 10.sup.3 rare-earth ions, and coupled to a targeting agent for the substance to be analyzed, under conditions conducive to their association with the sample substance to be analyzed; (ii) exciting the rare-earth ions of the particles by an illumination device having a power of at least 50 mW and an excitation intensity of at least 1 W/cm.sup.2; (iii) detecting the luminescence emission by the particles after single-photon absorption; and (iv) determining the presence and/or concentration of the substance by interpreting said luminescence measurement. This process can be used for in vitro diagnostic purposes and as an in vitro diagnostic kit.

This application features a method of forming a nanoporous layer. The method includes steps of reducing metal ions in a reverse micelle phase composition to form nanoparticles, removing surfactant from the composition to form clusters of the nanoparticles, dispensing the composition including the nanoparticle clusters dispersed in a liquid on a substrate, and drying to form the nanoporous layer. The nanoporous layer includes nanoparticles deposited to form a three dimensional network of irregularly shaped bodies. The nanoporous layer also includes a three dimensional network of intercluster spaces that are not occupied by the three dimensional network of irregularly shaped bodies.